Revisional endoscopic sleeve gastroplasty versus semaglutide and tirzepatide for weight recidivism after sleeve gastrectomy.

Bahdi F, Shah S, Dahoud F, Farooq M, Kozan P, Kim S, Sedarat A, Shen N, Thaker A, Kolb JM, Dutson E, Muthusamy VR, Issa D

Clinical obesity5 Feb 2025Cited by 7 (Europe PMC)

PMID39909715DOI10.1111/cob.70001PepBankPUB-39909715

Publisher page PubMedAsk about this study

Jump to 21 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study21

3 results from studies that gave the peptide. 3 results from people.

01HumanObservational studyEfficacy outcome
In patients with weight recidivism after sleeve gastrectomy, tirzepatide gave similar 12-month TBWL to R-ESG (13.2% versus 13.4%).
In plain wordsAfter sleeve gastrectomy, tirzepatide gave about the same weight loss at 12 months as a repeat endoscopic procedure.
Peptide
Tirzepatide
Outcome
No significant changeTBWL at 12 months versus R-ESG
Study
n: not reported in source
Comparator
R-ESG
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
TBWL
13.2%
tirzepatide, 12 months
TBWL
13.4%
R-ESG, 12 months
Source sentences
Summary
tirzepatide achieved similar 12-months TBWL% as R-ESG (13.2% vs. 13.4%, p = .9)
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective study of patients ≥18 years with prior SG treated with semaglutide, tirzepatide or R-ESG for weight recidivism between January 2019 and 2023 at large academic centre.
Report a problemFND-3990971501
02HumanObservational studyEfficacy outcome
In patients with weight recidivism after sleeve gastrectomy, tirzepatide gave significantly more 12-month TBWL than semaglutide (13.2% versus 8.1%).
In plain wordsAfter sleeve gastrectomy, tirzepatide gave more weight loss at 12 months than semaglutide.
Peptide
Tirzepatide
Outcome
IncreaseTBWL at 12 months versus semaglutide
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
TBWL
13.2%
tirzepatide, 12 months
TBWL
8.1%
semaglutide, 12 months
Source sentences
Summary
and significantly more than semaglutide (13.2% vs. 8.1%, p = .04)
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective study of patients ≥18 years with prior SG treated with semaglutide, tirzepatide or R-ESG for weight recidivism between January 2019 and 2023 at large academic centre.
Report a problemFND-3990971502
03HumanObservational studyEfficacy outcome
In patients with weight recidivism after sleeve gastrectomy, semaglutide gave significantly less 12-month TBWL than tirzepatide (8.1% versus 13.2%).
In plain wordsAfter sleeve gastrectomy, semaglutide gave less weight loss at 12 months than tirzepatide.
Peptide
Semaglutide
Outcome
DecreaseTBWL at 12 months versus tirzepatide
Study
n: not reported in source
Comparator
Tirzepatide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
TBWL
8.1%
semaglutide, 12 months
TBWL
13.2%
tirzepatide, 12 months
Source sentences
Summary
and significantly more than semaglutide (13.2% vs. 8.1%, p = .04)
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective study of patients ≥18 years with prior SG treated with semaglutide, tirzepatide or R-ESG for weight recidivism between January 2019 and 2023 at large academic centre.
Report a problemFND-3990971503

Studies that did not test the peptide alone18

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

04HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
After sleeve gastrectomy, pooled GLP1/GIP-RA (including semaglutide) gave lower 3-month TBWL than R-ESG (4.3% versus 11.2%).
In plain wordsAfter sleeve gastrectomy, GLP-1 type drugs as a group gave less weight loss at 3 months than a repeat endoscopic procedure.
Peptide
Semaglutide
Outcome
DecreaseTBWL at 3 months, R-ESG versus GLP1/GIP-RA
Study
n: not reported in source
Comparator
R-ESG
Outcome group
Body weight · Metabolic and weight
Measurements
TBWL
4.3%
GLP1/GIP-RA, 3 months
TBWL
11.2%
R-ESG, 3 months
Source sentences
Summary
R-ESG offered higher TBWL% than GLP1/GIP-RA at 3 (11.2% vs. 4.3%, p < .001)
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective study of patients ≥18 years with prior SG treated with semaglutide, tirzepatide or R-ESG for weight recidivism between January 2019 and 2023 at large academic centre.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3990971504
05HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
After sleeve gastrectomy, pooled GLP1/GIP-RA (including semaglutide) gave lower 6-month TBWL than R-ESG (6.8% versus 13.5%).
In plain wordsAfter sleeve gastrectomy, GLP-1 type drugs as a group gave less weight loss at 6 months than a repeat endoscopic procedure.
Peptide
Semaglutide
Outcome
DecreaseTBWL at 6 months, R-ESG versus GLP1/GIP-RA
Study
n: not reported in source
Comparator
R-ESG
Outcome group
Body weight · Metabolic and weight
Measurements
TBWL
6.8%
GLP1/GIP-RA, 6 months
TBWL
13.5%
R-ESG, 6 months
Source sentences
Summary
6 (13.5% vs. 6.8%, p < .001)
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective study of patients ≥18 years with prior SG treated with semaglutide, tirzepatide or R-ESG for weight recidivism between January 2019 and 2023 at large academic centre.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3990971505
06HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
After sleeve gastrectomy, 12-month TBWL for pooled GLP1/GIP-RA (including semaglutide) was not significantly different from R-ESG (9.2% versus 13.4%).
In plain wordsAfter sleeve gastrectomy, GLP-1 type drugs as a group did not differ significantly from a repeat endoscopic procedure in weight loss at 12 months.
Peptide
Semaglutide
Outcome
No significant changeTBWL at 12 months, R-ESG versus GLP1/GIP-RA
Study
n: not reported in source
Comparator
R-ESG
Outcome group
Body weight · Metabolic and weight
Measurements
TBWL
9.2%
GLP1/GIP-RA, 12 months
TBWL
13.4%
R-ESG, 12 months
Source sentences
Summary
12 months (13.4% vs. 9.2%, p = .07)
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective study of patients ≥18 years with prior SG treated with semaglutide, tirzepatide or R-ESG for weight recidivism between January 2019 and 2023 at large academic centre.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3990971506
07HumanNot a test of Semaglutide aloneObservational studySafety outcome
After sleeve gastrectomy, adverse events did not differ significantly between R-ESG and pooled GLP1/GIP-RA (including semaglutide).
In plain wordsAfter sleeve gastrectomy, side effects were not clearly different between a repeat endoscopic procedure and GLP-1 type drugs as a group.
Peptide
Semaglutide
Outcome
No significant changeAdverse events, R-ESG versus GLP1/GIP-RA
Study
n: not reported in source
Comparator
R-ESG
Outcome group
Adverse events · Whole body
Source sentences
Summary
with no significant difference in AEs or change in metabolic parameters
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective study of patients ≥18 years with prior SG treated with semaglutide, tirzepatide or R-ESG for weight recidivism between January 2019 and 2023 at large academic centre.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3990971507
08HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
After sleeve gastrectomy, change in metabolic parameters did not differ significantly between R-ESG and pooled GLP1/GIP-RA (including semaglutide).
In plain wordsAfter sleeve gastrectomy, changes in blood measures were not clearly different between a repeat endoscopic procedure and GLP-1 type drugs as a group.
Peptide
Semaglutide
Outcome
No significant changeMetabolic parameters, R-ESG versus GLP1/GIP-RA
Study
n: not reported in source
Comparator
R-ESG
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
with no significant difference in AEs or change in metabolic parameters
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective study of patients ≥18 years with prior SG treated with semaglutide, tirzepatide or R-ESG for weight recidivism between January 2019 and 2023 at large academic centre.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3990971508
09HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
Pooled GLP1/GIP-RA (including semaglutide) gave lower 3-month TBWL in patients with prior sleeve gastrectomy than in patients with an intact stomach (4.3% versus 5.7%).
In plain wordsGLP-1 type drugs as a group gave less weight loss at 3 months after sleeve gastrectomy than in people with an intact stomach.
Peptide
Semaglutide
Outcome
DecreaseTBWL at 3 months, prior SG versus intact stomach
Study
n: not reported in source
Comparator
Patients with intact stomach
Outcome group
Body weight · Metabolic and weight
Measurements
TBWL
4.3%
prior SG, 3 months
TBWL
5.7%
intact stomach, 3 months
Source sentences
Summary
Compared to patients with intact stomach (n = 87), GLP1/GIP-RA achieved significantly lower TBWL% in patients with prior SG at 3 (4.3% vs. 5.7%, p = .02)
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective study of patients ≥18 years with prior SG treated with semaglutide, tirzepatide or R-ESG for weight recidivism between January 2019 and 2023 at large academic centre.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3990971509
10HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
Pooled GLP1/GIP-RA (including semaglutide) gave lower 6-month TBWL in patients with prior sleeve gastrectomy than in patients with an intact stomach (6.8% versus 9.2%).
In plain wordsGLP-1 type drugs as a group gave less weight loss at 6 months after sleeve gastrectomy than in people with an intact stomach.
Peptide
Semaglutide
Outcome
DecreaseTBWL at 6 months, prior SG versus intact stomach
Study
n: not reported in source
Comparator
Patients with intact stomach
Outcome group
Body weight · Metabolic and weight
Measurements
TBWL
6.8%
prior SG, 6 months
TBWL
9.2%
intact stomach, 6 months
Source sentences
Summary
6 (6.8% vs. 9.2%, p = .02)
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective study of patients ≥18 years with prior SG treated with semaglutide, tirzepatide or R-ESG for weight recidivism between January 2019 and 2023 at large academic centre.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3990971510
11HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
Pooled GLP1/GIP-RA (including semaglutide) gave lower 12-month TBWL in patients with prior sleeve gastrectomy than in patients with an intact stomach (9.2% versus 12.7%).
In plain wordsGLP-1 type drugs as a group gave less weight loss at 12 months after sleeve gastrectomy than in people with an intact stomach.
Peptide
Semaglutide
Outcome
DecreaseTBWL at 12 months, prior SG versus intact stomach
Study
n: not reported in source
Comparator
Patients with intact stomach
Outcome group
Body weight · Metabolic and weight
Measurements
TBWL
9.2%
prior SG, 12 months
TBWL
12.7%
intact stomach, 12 months
Source sentences
Summary
12 months (9.2% vs. 12.7%, p = .03)
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective study of patients ≥18 years with prior SG treated with semaglutide, tirzepatide or R-ESG for weight recidivism between January 2019 and 2023 at large academic centre.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3990971511
12HumanNot a test of Semaglutide aloneObservational studyOther
Medication refills were difficult in 41.3% of patients in the study.
In plain wordsRefilling the medicine was difficult for 41.3% of patients in the study.
Peptide
Semaglutide
Outcome
Not applicableDifficult medication refills
Study
n: not reported in source
Outcome group
Patterns of use · Whole body
Measurements
Patients with difficult refills
41.3%
study patients
Source sentences
Summary
Medication refills were difficult in 41.3% of patients.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective study of patients ≥18 years with prior SG treated with semaglutide, tirzepatide or R-ESG for weight recidivism between January 2019 and 2023 at large academic centre.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3990971512
13HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
After sleeve gastrectomy, pooled GLP1/GIP-RA (including tirzepatide) gave lower 3-month TBWL than R-ESG (4.3% versus 11.2%).
In plain wordsAfter sleeve gastrectomy, GLP-1 type drugs as a group gave less weight loss at 3 months than a repeat endoscopic procedure.
Peptide
Tirzepatide
Outcome
DecreaseTBWL at 3 months, R-ESG versus GLP1/GIP-RA
Study
n: not reported in source
Comparator
R-ESG
Outcome group
Body weight · Metabolic and weight
Measurements
TBWL
4.3%
GLP1/GIP-RA, 3 months
TBWL
11.2%
R-ESG, 3 months
Source sentences
Summary
R-ESG offered higher TBWL% than GLP1/GIP-RA at 3 (11.2% vs. 4.3%, p < .001)
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective study of patients ≥18 years with prior SG treated with semaglutide, tirzepatide or R-ESG for weight recidivism between January 2019 and 2023 at large academic centre.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3990971513
14HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
After sleeve gastrectomy, pooled GLP1/GIP-RA (including tirzepatide) gave lower 6-month TBWL than R-ESG (6.8% versus 13.5%).
In plain wordsAfter sleeve gastrectomy, GLP-1 type drugs as a group gave less weight loss at 6 months than a repeat endoscopic procedure.
Peptide
Tirzepatide
Outcome
DecreaseTBWL at 6 months, R-ESG versus GLP1/GIP-RA
Study
n: not reported in source
Comparator
R-ESG
Outcome group
Body weight · Metabolic and weight
Measurements
TBWL
6.8%
GLP1/GIP-RA, 6 months
TBWL
13.5%
R-ESG, 6 months
Source sentences
Summary
6 (13.5% vs. 6.8%, p < .001)
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective study of patients ≥18 years with prior SG treated with semaglutide, tirzepatide or R-ESG for weight recidivism between January 2019 and 2023 at large academic centre.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3990971514
15HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
After sleeve gastrectomy, 12-month TBWL for pooled GLP1/GIP-RA (including tirzepatide) was not significantly different from R-ESG (9.2% versus 13.4%).
In plain wordsAfter sleeve gastrectomy, GLP-1 type drugs as a group did not differ significantly from a repeat endoscopic procedure in weight loss at 12 months.
Peptide
Tirzepatide
Outcome
No significant changeTBWL at 12 months, R-ESG versus GLP1/GIP-RA
Study
n: not reported in source
Comparator
R-ESG
Outcome group
Body weight · Metabolic and weight
Measurements
TBWL
9.2%
GLP1/GIP-RA, 12 months
TBWL
13.4%
R-ESG, 12 months
Source sentences
Summary
12 months (13.4% vs. 9.2%, p = .07)
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective study of patients ≥18 years with prior SG treated with semaglutide, tirzepatide or R-ESG for weight recidivism between January 2019 and 2023 at large academic centre.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3990971515
16HumanNot a test of Tirzepatide aloneObservational studySafety outcome
After sleeve gastrectomy, adverse events did not differ significantly between R-ESG and pooled GLP1/GIP-RA (including tirzepatide).
In plain wordsAfter sleeve gastrectomy, side effects were not clearly different between a repeat endoscopic procedure and GLP-1 type drugs as a group.
Peptide
Tirzepatide
Outcome
No significant changeAdverse events, R-ESG versus GLP1/GIP-RA
Study
n: not reported in source
Comparator
R-ESG
Outcome group
Adverse events · Whole body
Source sentences
Summary
with no significant difference in AEs or change in metabolic parameters
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective study of patients ≥18 years with prior SG treated with semaglutide, tirzepatide or R-ESG for weight recidivism between January 2019 and 2023 at large academic centre.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3990971516
17HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
After sleeve gastrectomy, change in metabolic parameters did not differ significantly between R-ESG and pooled GLP1/GIP-RA (including tirzepatide).
In plain wordsAfter sleeve gastrectomy, changes in blood measures were not clearly different between a repeat endoscopic procedure and GLP-1 type drugs as a group.
Peptide
Tirzepatide
Outcome
No significant changeMetabolic parameters, R-ESG versus GLP1/GIP-RA
Study
n: not reported in source
Comparator
R-ESG
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
with no significant difference in AEs or change in metabolic parameters
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective study of patients ≥18 years with prior SG treated with semaglutide, tirzepatide or R-ESG for weight recidivism between January 2019 and 2023 at large academic centre.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3990971517
18HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
Pooled GLP1/GIP-RA (including tirzepatide) gave lower 3-month TBWL in patients with prior sleeve gastrectomy than in patients with an intact stomach (4.3% versus 5.7%).
In plain wordsGLP-1 type drugs as a group gave less weight loss at 3 months after sleeve gastrectomy than in people with an intact stomach.
Peptide
Tirzepatide
Outcome
DecreaseTBWL at 3 months, prior SG versus intact stomach
Study
n: not reported in source
Comparator
Patients with intact stomach
Outcome group
Body weight · Metabolic and weight
Measurements
TBWL
4.3%
prior SG, 3 months
TBWL
5.7%
intact stomach, 3 months
Source sentences
Summary
Compared to patients with intact stomach (n = 87), GLP1/GIP-RA achieved significantly lower TBWL% in patients with prior SG at 3 (4.3% vs. 5.7%, p = .02)
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective study of patients ≥18 years with prior SG treated with semaglutide, tirzepatide or R-ESG for weight recidivism between January 2019 and 2023 at large academic centre.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3990971518
19HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
Pooled GLP1/GIP-RA (including tirzepatide) gave lower 6-month TBWL in patients with prior sleeve gastrectomy than in patients with an intact stomach (6.8% versus 9.2%).
In plain wordsGLP-1 type drugs as a group gave less weight loss at 6 months after sleeve gastrectomy than in people with an intact stomach.
Peptide
Tirzepatide
Outcome
DecreaseTBWL at 6 months, prior SG versus intact stomach
Study
n: not reported in source
Comparator
Patients with intact stomach
Outcome group
Body weight · Metabolic and weight
Measurements
TBWL
6.8%
prior SG, 6 months
TBWL
9.2%
intact stomach, 6 months
Source sentences
Summary
6 (6.8% vs. 9.2%, p = .02)
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective study of patients ≥18 years with prior SG treated with semaglutide, tirzepatide or R-ESG for weight recidivism between January 2019 and 2023 at large academic centre.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3990971519
20HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
Pooled GLP1/GIP-RA (including tirzepatide) gave lower 12-month TBWL in patients with prior sleeve gastrectomy than in patients with an intact stomach (9.2% versus 12.7%).
In plain wordsGLP-1 type drugs as a group gave less weight loss at 12 months after sleeve gastrectomy than in people with an intact stomach.
Peptide
Tirzepatide
Outcome
DecreaseTBWL at 12 months, prior SG versus intact stomach
Study
n: not reported in source
Comparator
Patients with intact stomach
Outcome group
Body weight · Metabolic and weight
Measurements
TBWL
9.2%
prior SG, 12 months
TBWL
12.7%
intact stomach, 12 months
Source sentences
Summary
12 months (9.2% vs. 12.7%, p = .03)
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective study of patients ≥18 years with prior SG treated with semaglutide, tirzepatide or R-ESG for weight recidivism between January 2019 and 2023 at large academic centre.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3990971520
21HumanNot a test of Tirzepatide aloneObservational studyOther
Medication refills were difficult in 41.3% of patients in the study.
In plain wordsRefilling the medicine was difficult for 41.3% of patients in the study.
Peptide
Tirzepatide
Outcome
Not applicableDifficult medication refills
Study
n: not reported in source
Outcome group
Patterns of use · Whole body
Measurements
Patients with difficult refills
41.3%
study patients
Source sentences
Summary
Medication refills were difficult in 41.3% of patients.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective study of patients ≥18 years with prior SG treated with semaglutide, tirzepatide or R-ESG for weight recidivism between January 2019 and 2023 at large academic centre.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3990971521

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 2
9 Oct 2026, 03:07 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.